Galactoside inhibitor of galectins
US10526360B2 · kind B2 · utility
3Cited by
0References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 13, 2019 |
| Grant date | Jan 7, 2020 |
| Priority date | — |
| Expiry date | Aug 13, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/056
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.